GRAIL INC
GRALNASDAQTrading Snapshot
- Day Range
- $134.57 – $137.17
- 52-Week Range
- $41.50 – $134.42
- Volume
- $4.03B
- Avg Volume
- $5.12B
- Shares Outstanding
- 42.9M
- Next Earnings
- Oct 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $147M
- Last Q Revenue
- $45M
- P/E Ratio
- -13.6
- P/S Ratio
- 34.4x
- EPS (TTM)
- $-9.08
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +27.7%
Why Investors Own GRAL
- ✓High-growth profile — revenue up +14.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 4% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GRAIL INC
GRAL
StockOtter · stockotter.spaceAbout GRAIL INC
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a
Here's Why Grail Stock Surged 55% This Week
Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access. Galleri's efficacy vote was close, reflecting ongoing concerns about eff
GRAIL (NASDAQ:GRAL) CEO Joshua Ofman Sells 61,452 Shares
GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CEO Joshua Ofman sold 61,452 shares of the firm's stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total transactio
Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't?
There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval
The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics